Use of Intercurrent Remedy in the Homoeopathic Management of Psoriasis Vulgaris: A Case Report.

Introduction: Psoriasis is a chronic inflammatory dermatological condition characterized by well-demarcated erythematous scaly plaques. It affects the immune system of the body causing inflammation and hyper-proliferation of the skin, where a key role is played by immune dysfunction and psychological stress. Psoriasis is a relapsing and remitting disease which shows its affections primarily for skin. This makes it more difficult to treat as there often is a mental maintaining cause associated in the background. Homoeopathy is an ideal system of medicine for the treatment of such diseases which show affections for both physical and mental sphere. Whilst treating such diseases, the homoeopathic physician often faces challenges when the most indicated remedy stops acting after an initial amelioration. This demands the usage of an intercurrent remedy which removes the obstacles in the path of cure and brings about recovery in the patient. Case Summary: A 28-year-old female presented with thick, coppery red eruptions on ear pinnae, scalp, extensor surface of left hand, back and ankles laterally. Based on the totality of symptoms, she was prescribed Staphysagria 1M which initially provided relief to the patient. The case was stood still for several months during which both placebo and Staphysagria 10M were prescribed. Still there was no progress whatsoever, the case was retaken, but the totality and the remedy were same. This was a clear call for prescribing an anti-miasmatic remedy to remove the miasmatic block. The patient was prescribed Psorinum 1M as an intercurrent anti-miasmatic remedy with remarkable physically and mental recovery. Staphysagria 10 M was repeated which later removed all the lesions and restored the patient mentally too.

A Survey to Assess the Impact of COVID-19 Pandemic on Lifestyle in an Adult Age Group.

Context: A healthy lifestyle has been the need of the hour during the COVID 19 pandemic. Analyzing the current lifestyle patterns of many individuals can be the basis for finding solutions toward building a healthy future for India. Objectives: The study intended to evaluate the current lifestyles of adults in an urban setting in the midst of a pandemic and to examine the diseases that people could face with respect to their current lifestyles. Design: The research team performed a cross-sectional study. Setting: The survey was conducted in an urban setting in the Pimpri Chinchwad area of Pune, India. Participants: Participants were 500 men and women between the ages of 18 and 25. Outcome Measures: The research team created a survey with 13 multiple-choice questions. Results: The pandemic has taken a toll on people's mental and physical health. Social distancing and staying indoors for long periods are factors that have affected people's mental health. Conclusions: Efforts need to be made by individuals to focus not only on their physical health but also on their mental health.

The Efficacy of Homoeopathic Remedy: A Case Report of Adhesive Capsulitis.

Adhesive capsulitis, also known as frozen shoulder, is a condition characterized by pain and stiffness of the shoulder joint. Frozen shoulder is more common in women, though it can also occur in men. It occurs mainly after 50 years of age. This study has been conducted to evaluate the role of homoeopathic treatment in cases of frozen shoulder disorder. Homoeopathy has also demonstrated great efficacy in curing symptoms and reducing severity of frozen shoulder.

Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15.

Recombinant agonists that activate co-stimulatory and cytokine receptors have shown limited clinical anticancer utility, potentially due to narrow therapeutic windows, the need for coordinated activation of co-stimulatory and cytokine pathways and the failure of agonistic antibodies to recapitulate signaling by endogenous ligands. RTX-240 is a genetically engineered red blood cell expressing 4-1BBL and IL-15/IL-15Rα fusion (IL-15TP). RTX-240 is designed to potently and simultaneously stimulate the 4-1BB and IL-15 pathways, thereby activating and expanding T cells and NK cells, while potentially offering an improved safety profile through restricted biodistribution. We assessed the ability of RTX-240 to expand and activate T cells and NK cells and evaluated the in vivo efficacy, pharmacodynamics and tolerability using murine models. Treatment of PBMCs with RTX-240 induced T cell and NK cell activation and proliferation. In vivo studies using mRBC-240, a mouse surrogate for RTX-240, revealed biodistribution predominantly to the red pulp of the spleen, leading to CD8 + T cell and NK cell expansion. mRBC-240 was efficacious in a B16-F10 melanoma model and led to increased NK cell infiltration into the lungs. mRBC-240 significantly inhibited CT26 tumor growth, in association with an increase in tumor-infiltrating proliferating and cytotoxic CD8 + T cells. mRBC-240 was tolerated and showed no evidence of hepatic injury at the highest feasible dose, compared with a 4-1BB agonistic antibody. RTX-240 promotes T cell and NK cell activity in preclinical models and shows efficacy and an improved safety profile. Based on these data, RTX-240 is now being evaluated in a clinical trial.

Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic.

Checkpoint inhibitors and T-cell therapies have highlighted the critical role of T cells in anti-cancer immunity. However, limitations associated with these treatments drive the need for alternative approaches. Here, we engineer red blood cells into artificial antigen-presenting cells (aAPCs) presenting a peptide bound to the major histocompatibility complex I, the costimulatory ligand 4-1BBL, and interleukin (IL)-12. This leads to robust, antigen-specific T-cell expansion, memory formation, additional immune activation, tumor control, and antigen spreading in tumor models in vivo. The presence of 4-1BBL and IL-12 induces minimal toxicities due to restriction to the vasculature and spleen. The allogeneic aAPC, RTX-321, comprised of human leukocyte antigen-A*02:01 presenting the human papilloma virus (HPV) peptide HPV16 E711-19, 4-1BBL, and IL-12 on the surface, activates HPV-specific T cells and promotes effector function in vitro. Thus, RTX-321 is a potential 'off-the-shelf' in vivo cellular immunotherapy for treating HPV + cancers, including cervical and head/neck cancers.